-
Views
-
Cite
Cite
Christian Delles, Ulrike Raff, Albert Mimran, Jean P. Fauvel, Luis M. Ruilope, Roland E. Schmieder, Effects of Telmisartan and Ramipril on Adiponectin and Blood Pressure in Patients with Type 2 Diabetes, American Journal of Hypertension, Volume 21, Issue 12, December 2008, Pages 1330–1336, https://doi.org/10.1038/ajh.2008.297
Close - Share Icon Share
Abstract
Adiponectin is secreted by adipose tissue and may play a role in cardiovascular disease. We examined adiponectin levels in patients with type 2 diabetes who participated in the Telmisartan vs. Ramipril in Renal Endothelial Dysfunction (TRENDY) study.
A total of 87 patients were assessed at baseline and following 9 weeks treatment with the angiotensin-receptor blocker telmisartan (final dose, 80 mg; n = 45) or the angiotensin-converting enzyme inhibitor ramipril (final dose, 10 mg; n = 42). Adiponectin levels were measured in plasma by radioimmunoassay.
Adiponectin levels were inversely correlated with systolic (SBP; r = −0.240, P < 0.05) and diastolic (DBP; r = −0.227, P < 0.05) blood pressure at baseline and following treatment with telmisartan or ramipril (SBP: r = −0.228, P < 0.05; DBP: r = −0.286, P < 0.05). Changes in adiponectin levels were related to changes in SBP (r = −0.357, P < 0.01) and DBP (r = −0.286, P < 0.01). There was a significant increase in adiponectin levels in the telmisartan (0.68 (95% confidence interval (CI), 0.27 to 1.10) µg/ml, P < 0.01) but not in the ramipril group (0.17 (95% CI, −0.56 to 0.90) µg/ml, P = 0.67). Blood pressure reduction in the telmisartan group (ΔSBP: −13.5 (95% CI, −17.0 to −10.0) mm Hg; ΔDBP: −7.6 (95% CI, −9.8 to −5.3) mm Hg, each P < 0.001) was significantly (P ≤ 0.01 for SBP and P < 0.01 for DBP) greater than in the ramipril group (ΔSBP: −6.1 (95% CI, −6.2 to −2.0) mm Hg; ΔDBP: −2.7 (95% CI, −5.0 to −0.5) mm Hg; P < 0.01 and P < 0.05, respectively).
Adiponectin is correlated with blood pressure in patients with type 2 diabetes. Whether increased adiponectin contributes to the blood pressure–lowering effect of telmisartan needs further study.
